By Fineline Cube 
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its antibody-drug conjugate (ADC) BL-M09D1 has received clinical trial clearance from China’s National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. This marks a significant milestone in the development of this innovative therapeutic candidate.
BL-M09D1: Technology Platform
While the specific target of BL-M09D1 remains undisclosed, the company has revealed that the candidate utilizes the same small-molecule technology platform as its EGFR/HER3-targeted ADC BL-B01D1. This platform includes an identical “linker+toxin” payload system, which has been designed to enhance the drug’s efficacy and safety profile.
Clinical Development and Future Outlook
With clinical trial clearance secured, Sichuan Biokin is poised to initiate studies to evaluate the safety and efficacy of BL-M09D1 in patients with advanced solid tumors. This development underscores the company’s commitment to advancing its pipeline of innovative ADC therapies, building on the success of its existing platforms.-Fineline Info & Tech